ArriVent BioPharma Total Current Liabilities

ArriVent BioPharma (AVBP) currently reports a total current liabilities of $25M as of March 2026. That compares with $13M in the prior-year period — up 93.0% year over year. Use the charts on this page to explore ArriVent BioPharma's total current liabilities history and peer comparisons.

ArriVent BioPharma's total current liabilities increased from $13M to $25M — a 93.0% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ArriVent BioPharma reported $25M in total current liabilities as of March 2026. That compares with $13M in the prior-year period — up 93.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $25M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for ArriVent BioPharma, and consider following AVBP for alerts when major investors trade the stock.